[1] |
NING Xiao, GAO Guanghui, JIN Shaoming, LIU Tongtong, PEI Yusheng, CAO Jin.
Determination of erythromycin ointment content based on on-line column switching and liquid chromatography
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 152-155.
|
[2] |
ZHANG Yuqi, XU Xinyi, ZHU Lan, ZHU Yan.
Comparison standard terminology for pharmaceutical dose forms
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(8): 904-910.
|
[3] |
YAO Keyu, ZHANG Shuqi, JIN Rui, LIU Lihong, ZHU Yan.
Comparative study on data set of drug-induced liver injury
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 568-573.
|
[4] |
FU Lu, JIN Yan, PENG Huasheng, YUAN Yuan.
Classification and influencing factors of toxicity of Chinese medicine based on ancient books of materia medica
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(4): 349-352.
|
[5] |
CONG Duanduan, XUE Wei, LIU Yue, QI Wenyuan, LIU Xiaohui, WANG Juan, LI Kexin, HU Xin.
Management of Safety Information in Prescription Drug Labeling in China, Japan and the United States
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(3): 245-249.
|
[6] |
TIAN Chunhua, XIA Dongsheng.
"Double Classification" Management of Prescription Drugs and Non-prescription Drugs in China based on British System
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(12): 883-884.
|
[7] |
ZHU Lan, Shao Bo, XIA Dongsheng.
Selection and Switch-to-OTC of Chinese Patent Medicines in China
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(11): 785-789.
|
[8] |
YUAN Li, YANG Yue.
Research on the Differences and Correlation Between‘Serious’ and ‘Severe’ Adverse Drug Reactions/Events
[J]. Chinese Journal of Pharmacovigilance, 2016, 13(8): 484-488.
|
[9] |
WANG Pei-jie, WANG Jia-lun, YI Zhi-wei, Dong Yan-fei, WANG Pu.
Literature Analysis of 40 Cases of Adverse Drug Reactions of Nonprescription Chinese Patent Medicines for Diseases of Throat Department
[J]. Chinese Journal of Pharmacovigilance, 2015, 12(11): 690-692.
|
[10] |
ZHAO Liang, XU Bing-xin, LAN Bing-xin.
Practice of High-risk Drug Management Strategies
[J]. Chinese Journal of Pharmacovigilance, 2014, 11(3): 182-184.
|
[11] |
LIU Chun-guang, JIN Feng ,YUAN Guo-hui .
The History and Expectation of Classification Management of Drugs in China
[J]. Chinese Journal of Pharmacovigilance, 2013, 10(6): 348-351.
|
[12] |
TANG Ren, XIA Dong-sheng ,TIAN Chun-hua, WANG Chun-ting.
Stage Characteristics of Prescription and Nonprescription Switch in China
[J]. Chinese Journal of Pharmacovigilance, 2013, 10(5): 278-281.
|
[13] |
WEN Qiang, TANG Xiao-hong, LIU Xiao-lan, ZHU Shu-bing, XIONG Xue-cai.
The Study on Classification of Medical Device Adverse Events Based on Epidemiological Model of Injure
[J]. Chinese Journal of Pharmacovigilance, 2011, 8(11): 658-661.
|
[14] |
XIA, Dong-sheng.
Discussion on Rational Use of Non-prescription Drugs and Adverse Reactions Avoidance Strategy
[J]. Chinese Journal of Pharmacovigilance, 2010, 7(6): 343-346.
|